Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan + melphalan high-dose chemotherapy with autologous PBSC support in recurrent neuroblastoma and Ewing's sarcoma
2015-002584-41Phase 2Terminated
- Sponsor
- Masaryk University
- Start
- Oct 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treosulfan and melphalan in neuroblastoma and Ewing sarcoma, sponsored by Masaryk University. Primary endpoint: Primary endpoint of efficacy. Started Oct 2016; status: terminated.
02
Drugs
treosulfanmelphalan
03
Conditions
neuroblastomaEwing sarcoma
Beyond the preview
Go deeper on 2015-002584-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002584-41.